Form 4: Vir Biotechnology Director Receives Equity Grant

Director Norbert W. Bischofberger acquired 8,000 restricted stock units and 16,000 stock options as part of an equity incentive plan.

Summary

• Director Norbert W. Bischofberger was granted 8,000 restricted stock units (RSUs) on May 27, 2026.
• The director also received a stock option grant for 16,000 shares with an exercise price of $9.10.
• Both the RSUs and the stock options are scheduled to vest in full on May 27, 2027.
• Following these transactions, the director holds 21,333 shares directly and 10,667 shares indirectly through Nextquest, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership talent via standard equity incentive plan mechanisms.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of stock options and vesting of RSUs.

Risks

• Market price volatility affecting the value of the granted equity instruments.
• General risks associated with the biotechnology sector, including clinical trial outcomes and regulatory approval timelines.

Future Outlook

The filing does not provide forward-looking business guidance, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology industry to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of RSUs and stock options with a one-year cliff vesting period is consistent with standard compensation practices for non-employee directors in mid-cap biotech firms.
• The grant size is typical for a director-level equity incentive package.

Related Party Transactions

• The director maintains an indirect interest in 10,667 shares held by Nextquest, LLC, where he serves as a managing member.

Stakeholder Impact

• Minimal impact on shareholders; the grants represent a standard component of director compensation.

Next Steps

• Vesting of equity grants on May 27, 2027.

Key Dates

Keywords

Vir Biotechnology, VIR, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation